Shopping Cart
- Remove All
- Your shopping cart is currently empty
GP531 is a second-generation adenosine regulating agent. It is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | GP531 is a second-generation adenosine regulating agent. It is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia. |
In vivo | GP531 administration does not alter heart rate or mean aortic pressure but significantly improves left ventricular function by reducing end-diastolic pressure, volumes, and wall stress, while enhancing ejection fraction (EF), deceleration time of early mitral inflow velocity, and the slope of end-systolic pressure-volume relationship (PVR), without an increase in myocardial oxygen consumption (MVO2). At low doses, GP531 diminishes infarct size by 34% and the no-reflow zone extent by 31% compared to control, with high doses achieving reductions of 22% and 16%, respectively. Unlike adenosine, GP531 does not impact overall hemodynamics or blood flow, showcasing its efficacy in mitigating ischemic/reperfusion injury severity at lower doses without inducing adverse hemodynamic events such as bradycardia and hypotension. |
Molecular Weight | 347.37 |
Formula | C16H21N5O4 |
Cas No. | 142344-87-4 |
Relative Density. | 1.31g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (359.85 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.